Full-Time

IT Manager

GxP Systems & Compliance

Deadline 8/11/27
Rocket Pharmaceuticals

Rocket Pharmaceuticals

201-500 employees

Develops gene therapies with AAV platform

Compensation Overview

$120k - $160k/yr

+ Bonus + Equity awards

Cranbury, NJ, USA

In Person

Bachelor's

Category
IT & Security (1)
Required Skills
ERP

Get referred to Rocket Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree in information technology, Computer Science, Engineering, Life Sciences, or equivalent relevant experience.
  • Five to eight years of experience supporting IT systems in a GxP-regulated pharmaceutical, biotechnology, contract development and manufacturing, manufacturing, or quality control environment.
  • Hands-on experience supporting GxP manufacturing, QC laboratory, automation, or IT/OT systems, including instrument-connected PCs, networked devices, servers, applications, and validated systems.
  • Working knowledge of current Good xPractice, GAMP 5, 21 CFR Part 11, EU Annex 11, ALCOA+, data integrity, computerized system validation, change control, deviation/CAPA, and audit readiness expectations.
  • Experience with GxP systems and platforms such as LIMS, CDS, MES, BMS, SCADA, Empower, laboratory instruments, manufacturing systems, Veeva Vault, eQMS, ERP, or similar regulated applications.
  • Experience with system administration, access management, backup and restore processes, patching coordination, disaster recovery, periodic reviews, audit trail support, and controlled documentation.
  • Ability to troubleshoot technical issues across applications, endpoints, infrastructure, laboratory instruments, and manufacturing support systems while maintaining compliance with approved procedures.
  • Strong documentation skills, including creating or maintaining SOPs, work instructions, runbooks, validation documentation, support records, incident records, and audit-ready evidence.
  • Ability to partner with Manufacturing, QC, QA, Validation, Automation, Facilities, Cybersecurity, Infrastructure, and vendor teams in a regulated operating environment.
  • Ability to support critical GxP operations through organization, communication, problem-solving, customer service, and prioritization.
  • Ability to work outside standard business hours occasionally for GxP activities, implementations, upgrades, maintenance, audits, inspections, and critical issue resolution.
  • Ability to lift, carry, push, or pull equipment and materials weighing up to 25 pounds occasionally.
  • Ability to wear required personal protective equipment and comply with safety, security, and GxP requirements in regulated environments.
  • Ability to work in office, regulated laboratory, manufacturing, and data center environments.
Responsibilities
  • Provide daily IT operational support for GxP manufacturing, QC laboratory, and technical operations systems, including application issues, instrument-connected workstations, networked devices, infrastructure components, and user access requests.
  • Maintain reliable, compliant, and secure operation of GxP systems such as LIMS, CDS, MES, BMS, SCADA, Empower, laboratory instruments, cleanroom systems, manufacturing systems, and related GxP applications.
  • Partner with Manufacturing, QC, QA, Validation, Automation, Facilities, and business stakeholders to triage incidents, resolve service requests, manage escalations, and minimize operational disruption.
  • Support GxP change control activities, including impact assessment, implementation planning, testing coordination, validation deliverables, deployment readiness, and post-implementation verification.
  • Assist with computerized system validation and qualification activities, including IQ/OQ/PQ, user acceptance testing, traceability, periodic reviews, system retirement, and maintenance of audit-ready documentation.
  • Lead or support deviation, incident, problem, CAPA, and effectiveness check records related to GxP computerized systems and ensure timely completion of assigned actions.
  • Manage system administration processes for GxP applications, including user access provisioning, role-based access, periodic access reviews, audit trail support, backup and restore oversight, and data integrity controls.
  • Coordinate patching, vulnerability remediation, endpoint maintenance, server support, disaster recovery testing, and business continuity activities for GxP systems in alignment with IT and quality procedures.
  • Develop, maintain, and improve SOPs, work instructions, support runbooks, knowledge articles, system inventories, configuration records, and operational support procedures for GxP systems.
  • Manage relationships with vendors and external service providers to ensure timely support, compliant service delivery, effective issue escalation, and completion of maintenance or qualification activities.
  • Track and report GxP support metrics, system health indicators, recurring issues, service levels, and continuous improvement opportunities.
  • Support internal audits, external inspections, vendor audits, and quality reviews by preparing documentation, responding to findings, and driving remediation activities related to GxP IT support operations.
Desired Qualifications
  • An advanced degree is a plus.
Rocket Pharmaceuticals

Rocket Pharmaceuticals

View

Rocket Pharmaceuticals develops gene therapies for severe and rare inherited diseases. It uses an AAV (Adeno-Associated Virus) platform to deliver corrected genes directly into patients, with the goal of producing a therapeutic protein in targeted cells of the heart, liver, eye, or central nervous system to modify the disease. The therapy work involves engineering AAV constructs so the corrected gene is expressed in diseased cells. The company aims to create first-in-class or best-in-class treatments and generates revenue through partnerships with larger pharma companies, grants, and potential future sales of approved therapies. Core values include Trust, Generosity, Curiosity, and Elevation, guiding a patient-centric approach that puts families first and supports ongoing scientific advancement. Overall goal: provide life-changing gene therapies for patients with few options and expand treatment options for rare genetic disorders.

Company Size

201-500

Company Stage

IPO

Headquarters

Cranbury Township, New Jersey

Founded

2015

Get referred to Rocket Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • April 2026 PRV sale delivered $180 million and runway into Q2 2028.
  • August 3, 2026 RP-A501 update reduced Danon execution risk before the second-half 2026 readout.
  • March 27, 2026 KRESLADI approval and launch establish Rocket’s first commercial revenue engine.

What critics are saying

  • August 3, 2026 RP-A501 safety only covers three patients; one setback kills Danon expansion.
  • June 2025 securities litigation over RP-A501 disclosures threatens management distraction and damages.
  • Rocket’s April 2026 PRV sale and March 2026 ATM show persistent dilution dependence; runway ends if launch stalls.

What makes Rocket Pharmaceuticals unique

  • March 27, 2026 KRESLADI became Rocket’s first FDA-approved gene therapy.
  • Rocket owns proprietary AAV manufacturing and multi-year cardiac gene therapy datasets.
  • RP-A501 and RP-A701 target high-need inherited cardiomyopathies with few direct competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Holidays

Wellness Program

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
May 11th, 2026
Rocket Pharmaceuticals Q1 loss wider than expected, Kresladi gene therapy launch underway

Rocket Pharmaceuticals shares fell on Friday after the company reported first-quarter 2026 results that missed expectations. The company posted a loss of 42 cents per share, wider than the Zacks Consensus Estimate of 41 cents, and recorded no revenues during the quarter. General and administrative expenses declined 39.8% year over year to $17.1 million, whilst research and development expenses fell 12.2% to $31.5 million, reflecting disciplined spending following organisational restructuring. The company ended the quarter with $144.4 million in cash and investments. In March, the FDA granted accelerated approval to Rocket's gene therapy Kresladi for treating severe leukocyte adhesion deficiency-I. The company also recently agreed to sell its Priority Review Voucher for $180 million to support its cardiovascular pipeline.

Associated Press
May 7th, 2026
Rocket Pharma sells rare disease voucher for $180M, extends cash runway to Q2 2028

Rocket Pharmaceuticals reported first quarter 2026 financial results, highlighting progress across its cardiovascular gene therapy pipeline. The company received FDA accelerated approval for KRESLADI for severe leukocyte adhesion deficiency-I in March 2026 and subsequently sold its Rare Pediatric Disease Priority Review Voucher for $180 million in April. The company has reinitiated dosing in its pivotal Phase 2 study of RP-A501 for Danon disease following a clinical hold lift, with a programme update expected in the second half of 2026. First patient dosing for RP-A701 in BAG3-associated dilated cardiomyopathy is anticipated mid-2026. First quarter net loss was $47.6 million, down from $61.3 million year-over-year. Cash, cash equivalents and investments totalled $144.4 million as of 31 March 2026, which together with PRV proceeds extends the expected cash runway into the second quarter of 2028.

Pulse 2.0
Apr 28th, 2026
Rocket Pharmaceuticals raises $180M selling FDA priority review voucher to fund gene therapy pipeline

Rocket Pharmaceuticals has raised $180 million through the sale of its Rare Pediatric Disease Priority Review Voucher, extending its cash runway into the second quarter of 2028. The voucher was awarded following the FDA's accelerated approval of KRESLADI, the company's gene therapy for a rare paediatric disease. The proceeds will support Rocket's cardiovascular gene therapy pipeline, which includes three clinical-stage programmes targeting major inherited cardiomyopathy subtypes: Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy. These conditions collectively affect over 100,000 patients in the US and EU. The commercial-stage biotechnology company, which trades on Nasdaq under ticker RCKT, maintains proprietary AAV manufacturing capabilities and multi-year efficacy and safety data in cardiac gene therapy.

Jadis Press
Mar 29th, 2026
Rocket Pharmaceuticals receives FDA approval for KRESLADI gene therapy.

Rocket Pharmaceuticals receives FDA approval for KRESLADI gene therapy. Alexandra Moore Published Mar 30, 2026 - 04:18 Smallest Font Largest Font Rocket Pharmaceuticals recently announced a significant regulatory achievement, as the U.S. Food and Drug Administration (FDA) granted approval for KRESLADI. This gene therapy targets a rare pediatric disorder, marking the company's inaugural marketed product and a pivotal regulatory success after an extended review process, as reported by Detik Finance. This approval is particularly notable as KRESLADI becomes the first FDA-sanctioned gene therapy for this specific condition. The development positions Rocket Pharmaceuticals to establish a commercial presence within the ultra-rare disease market. Beyond the product approval itself, Rocket Pharmaceuticals also secured a Rare Pediatric Disease Priority Review Voucher. This asset offers biotech companies a valuable monetization opportunity. Management is actively exploring various strategic options for the voucher to bolster the company's financial flexibility. The company further stated its intentions to make KRESLADI accessible to eligible patients across the United States. Rocket Pharmaceuticals has indicated a controlled, rather than widespread, commercial rollout for KRESLADI. Recent company disclosures describe a tailored commercial strategy designed to address the very limited patient population. Reuters previously reported that the launch is anticipated to commence through a select number of specialized treatment centers. As of December 31, 2025, Rocket Pharmaceuticals held $188.9 million in cash, cash equivalents, and investments. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) operates as a biotechnology firm dedicated to developing genetic therapies for various rare disorders. Its research pipeline encompasses both lentiviral and AAV-based programs, which are aimed at addressing immunological and cardiovascular diseases.

Business Wire
Mar 27th, 2026
FDA approves Rocket Pharmaceuticals' KRESLADI for severe LAD-I in pediatric patients

Rocket Pharmaceuticals has received FDA accelerated approval for KRESLADI, a gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) without an available matched sibling donor for transplant. The approval is based on increased neutrophil CD18 and CD11a surface expression, with continued approval contingent on verification of clinical benefit. LAD-I is an ultra-rare genetic disease affecting approximately one in 100,000 to 200,000 live births in the US, with two-thirds classified as severe. Patients suffer from recurrent, life-threatening bacterial and fungal infections requiring frequent hospitalisation. The FDA granted Rocket a Rare Pediatric Disease Priority Review Voucher, which the company intends to monetise. KRESLADI is now available to eligible patients in the United States through www.KRESLADI.com.